Comparative Pharmacology
Head-to-head clinical analysis: NETARSUDIL MESYLATE versus RHOPRESSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NETARSUDIL MESYLATE versus RHOPRESSA.
NETARSUDIL MESYLATE vs RHOPRESSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Netarsudil mesylate is a Rho-associated protein kinase (ROCK) inhibitor. It inhibits ROCK1 and ROCK2, leading to relaxation of trabecular meshwork smooth muscle cells and increased aqueous humor outflow through the conventional (trabecular) pathway, thereby reducing intraocular pressure.
Selective alpha-2 adrenergic receptor agonist; reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow.
0.4 mg intravenously every 3 weeks over 60 minutes.
One drop of 0.02% ophthalmic solution in the affected eye(s) three times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 7-8 hours in healthy adults, allowing for twice-daily dosing in clinical practice.
Terminal elimination half-life is approximately 45 minutes following topical ophthalmic administration, with clinical IOP-lowering effect persisting beyond 24 hours due to receptor binding kinetics.
Primarily hepatic metabolism followed by biliary and fecal excretion; renal excretion of unchanged drug is negligible (<5%).
Primarily hepatic metabolism via CYP2C9 and CYP3A4; renal excretion accounts for <1% of unchanged drug; biliary/fecal excretion accounts for approximately 60% of the dose as metabolites.
Category C
Category C
Rho Kinase Inhibitor
Rho Kinase Inhibitor